Sartorius AG (XSWX:SRT3) Other Stockholders Equity: CHF2,194 Mil (As of Mar. 2026)


XSWX:SRT3 Sartorius AG XSWX:SRT3
82 GF Score
Price CHF207.80
GF Value CHF228.12
! 9 Warning Signs
View Full Analysis

What is Sartorius AG Other Stockholders Equity?

Sartorius AG XSWX:SRT3 +0.29% 82 Other Stockholders Equity is CHF2,194 Mil as of Mar. 2026. GuruFocus rates XSWX:SRT3 with a GF Score™ of 82/100 and a GF Value™ of CHF228.12. The stock has 9 warning signs investors should review.

Sartorius AG's Other Stockholders Equity for the quarter that ended in Mar. 2026 was CHF2,194 Mil.

Sartorius AG's quarterly Other Stockholders Equity increased from Sep. 2025 (CHF2,199 Mil) to Dec. 2025 (CHF2,231 Mil) but then declined from Dec. 2025 (CHF2,231 Mil) to Mar. 2026 (CHF2,194 Mil).

Sartorius AG's annual Other Stockholders Equity increased from Dec. 2023 (CHF1,843 Mil) to Dec. 2024 (CHF2,288 Mil) but then declined from Dec. 2024 (CHF2,288 Mil) to Dec. 2025 (CHF2,231 Mil).

Sartorius AG Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sartorius AG's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius AG Other Stockholders Equity Chart

Sartorius AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,195.32 1,852.15 1,842.96 2,288.19 2,231.13

Sartorius AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,288.19 2,198.45 2,198.81 2,231.13 2,193.79
XSWX:SRT3
82GF Score
Sartorius AG XSWX:SRT3
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius AG Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of CHF2,194 Mil mean?
Sartorius AG (XSWX:SRT3) has a Other Stockholders Equity of CHF2,194 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sartorius AG and its competitors.
Is Sartorius AG's Other Stockholders Equity too high?
Sartorius AG's current Other Stockholders Equity is CHF2,194 Mil. Overall, Sartorius AG has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Other Stockholders Equity compare to ISRG and BDX?
Sartorius AG's Other Stockholders Equity of CHF2,194 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sartorius AG and its competitors. Sartorius AG's current Other Stockholders Equity is CHF2,194 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Sartorius AG (XSWX:SRT3) has a current Other Stockholders Equity of CHF2,194 Mil. The stock's GF Value™ is CHF228.12, compared to a current price of CHF207.80 — trading 8.9% below its estimated fair value. The current Other Stockholders Equity is CHF2,194 Mil. Sartorius AG's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Sartorius AG (XSWX:SRT3), the current Other Stockholders Equity is CHF2,194 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius AG (XSWX:SRT3) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of CHF207.80 is trading 8.9% below its estimated GF Value™ of CHF228.12.

Key valuation signals for XSWX:SRT3:

  • Other Stockholders Equity: CHF2,194 Mil
  • GF Value™: CHF228.12 vs. price of CHF207.80 (8.9% below fair value)
  • GF Score™: 82/100 with 9 warning signs

No single metric tells the full story. See the XSWX:SRT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
82GF Score

Get the complete analysis for XSWX:SRT3

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF207.80
Price
CHF228.12
GF Value